Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vutiglabridin in Early Parkinson's Disease
NCT06329141Phase 2Completed
- Sponsor
- Glaceum
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vutiglabridin in Parkinson's disease (PD), sponsored by Glaceum. Started Jul 2024; status: completed.
02
Drugs
vutiglabridin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06329141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06329141.